<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30388235</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1945-7197</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>The Journal of clinical endocrinology and metabolism</Title>                <ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation>            </Journal>            <ArticleTitle>Serum levels of activins, follistatins and growth factors in neoplasms of the breast: A case-control study.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2018-01581</ELocationID>            <Abstract>                <AbstractText Label="Context" NlmCategory="UNASSIGNED">Breast cancer is the most common malignancy in women. Non- invasive biomarkers are needed for its early diagnosis and/or prognosis.</AbstractText>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">The aim of this case-control study was the comparison of serum activins, follistatins and members of the insulin-growth factor (IGF) family levels in women with benign vs. malignant breast neoplasms vs. apparently healthy controls.</AbstractText>                <AbstractText Label="Design and Patients" NlmCategory="UNASSIGNED">Women with breast benign (N=100) or malignant tumors (N=145) and disease-free controls (N=100) were recruited. Women with breast cancer were subsequently subdivided into recently-diagnosed/treatment-na√Øve (N=112) and chemotherapy-treated (N=33) ones. Anthropometric, demographic, biochemical and histological data were recorded.</AbstractText>                <AbstractText Label="Setting" NlmCategory="UNASSIGNED">A breast cancer clinic in Thessaloniki, Greece.</AbstractText>                <AbstractText Label="Main outcome measures" NlmCategory="UNASSIGNED">Serum levels of activin-A, activin-B, follistatin, follistatin-like (FSTL)-3, total IGF-1, total and intact IGF binding protein (IGFBP)-4 and pregnancy-associated plasma protein-A (PAPP-A) were measured with highly specific ELISA kits.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In adjusted comparisons, significant differences in FSTL-3, total and intact IGFBP-4, PAPP-A and total IGF-1 were observed between groups. In logistic regression analysis, primarily total IGFBP-4 levels were independently associated with the overall presence of breast malignancy. FSTL-3 was the only variable that could distinguish between a benign vs. malignant breast mass. In linear regression analysis, FSTL-3 was independently associated with tumor size.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer. Future mechanistic and longitudinal studies and/or clinical trials are needed to explore the efficacy of these molecules as non-invasive biomarkers and their possible therapeutic potential in breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Panagiotou</LastName>                    <ForeName>Grigorios</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Papakonstantinou</LastName>                    <ForeName>Eleni</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vagionas</LastName>                    <ForeName>Anastasios</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Unit, Theagenio Cancer Hospital, Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Polyzos</LastName>                    <ForeName>Stergios A</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mantzoros</LastName>                    <ForeName>Christos S</ForeName>                    <Initials>CS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Clin Endocrinol Metab</MedlineTA>            <NlmUniqueID>0375362</NlmUniqueID>            <ISSNLinking>0021-972X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30388235</ArticleId>            <ArticleId IdType="pii">5150476</ArticleId>            <ArticleId IdType="doi">10.1210/jc.2018-01581</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>